About Us
TRIPLN®
NuSirt has developed TRIPLN®, a combination of leucine; metformin, an anti-diabetic; and sildenafil, a vasodilator.
We have preclinical and phase 2 clinical data supporting the ability of TRIPLN® to mitigate metabolic-associated fatty liver disease, metabolic function-associated steatohepatitis, obesity, type 2 diabetes (T2D), and hypertension.
A Phase 2 randomized controlled clinical trial of TRIPLN® in approximately 120 hypertensive patients is scheduled to begin in third quarter 2026. To conduct this trial, NuSirt has received a federal $2.1 million Small Business Innovation Research (SBIR) grant. Final readout is scheduled for 2027.
LEUSIX®
NuSirt produces LEUSIX®, a dietary supplement comprising leucine and vitamin B6 (pyridoxine). Although vitamin B6 has been sold individually for fat loss, it produces little or no clinical efficacy by itself. By pairing it with leucine, LEUSIX® provides consumers with a groundbreaking method of protecting cardiometabolic health and managing weight. A study conducted in obese patients corroborates the ability of LEUSIX®, accompanied by mild lifestyle modification, to increase weight loss, preserve muscle mass, and reduce insulin resistance.
For more information on LEUSIX®, please visit the NuSirt Health website.
Our Team
